Melphalan Hikma (Melphalan)

Melphalan acts by adding alkyl groups to DNA, primarily at the N7 position of guanine. This creates cross‑links that prevent DNA strands from separating, blocking replication and transcription, which triggers apoptosis in rapidly dividing cancer cells.

The dose of melphalan is individualized by the prescribing physician based on the specific indication, patient weight, renal function and treatment protocol. Only a qualified healthcare professional should determine the appropriate dosing schedule.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm, and it is excreted in breast milk. Women who are pregnant, planning to become pregnant, or nursing should discuss alternative therapies with their oncologist.

To request Melphalan Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with agents such as cyclophosphamide, melphalan has a broader spectrum of activity against both hematologic and solid tumours and forms more stable DNA cross‑links. However, its toxicity profile, especially myelosuppression, may be more pronounced, requiring careful monitoring.

Melphalan Hikma should be stored at 2‑8 °C, protected from light, and kept in its original container. It must not be frozen or shaken, and any unused portion should be discarded according to local regulations after the recommended storage period.

Melphalan Hikma is supplied for intravenous infusion. It is administered by a qualified healthcare professional under aseptic conditions, typically diluted in a compatible IV solution and infused over a prescribed period as part of a chemotherapy regimen.

The most serious risks include severe myelosuppression leading to life‑threatening infections, secondary malignancies such as therapy‑related leukemia, pulmonary toxicity, renal impairment and hemorrhagic cystitis. Patients should be monitored closely for these complications throughout treatment.

Melphalan is contraindicated in patients with known hypersensitivity to melphalan or other alkylating agents, in pregnant or nursing women, and in individuals with severe bone‑marrow failure or uncontrolled renal or hepatic dysfunction. A thorough medical assessment is required before initiating therapy.